Flex Pharma Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Flex Pharma's estimated annual revenue is currently $1.6M per year.(i)
  • Flex Pharma's estimated revenue per employee is $201,000

Employee Data

  • Flex Pharma has 8 Employees.(i)
  • Flex Pharma grew their employee count by 0% last year.

Flex Pharma's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M3240%$634MN/A
#2
$47.8M2380%N/AN/A
#3
$2.4M12-52%N/AN/A
#4
$25.7M12839%N/AN/A
#5
$12.9M64129%N/AN/A
#6
$23.9M1198%$113MN/A
#7
$0.3M30%N/AN/A
#8
$10.3M51-14%N/AN/A
#9
$1.8M367-4%$538MN/A
#10
$50M2493%N/AN/A
Add Company

What Is Flex Pharma?

Our Company: Novel Treatments for Neuromuscular Disorders. Flex Pharma is a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders, and has demonstrated human efficacy related to muscle cramping. Novel Treatments for Neuromuscular Disorders, including Muscle Cramps. There is currently no proven or effective product for muscle cramps and spasms. Most muscle cramps are not caused by dehydration, lactic acid, electrolyte imbalance, or muscle tightness. That is why popular remedies like sports drinks, bananas, magnesium tablets, and stretching are usually ineffective. New research has shown that cramps and spasms do not originate in the muscle itself, but are caused instead by a neural mechanism: excessive firing of the motor neurons in the spinal cord that control muscle contraction. Flex Pharma is developing products to address muscle cramps and spasms by halting repetitive firing of the motor neurons. Our founders include professors from Harvard Medical School and Rockefeller University (Nobel prize, 2003). Preliminary testing of Flex Pharma's product in humans has shown that it can relieve electrically induced muscle cramps in minutes, and the effect lasts for hours.

keywords:N/A

N/A

Total Funding

8

Number of Employees

$1.6M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Flex Pharma News

2022-04-20 - Transient Receptor Potential Cation Channel Subfamily V ...

Amgen Inc, Amorepacific Corp, BCN Peptides SA, Centrexion Therapeutics Corp, Daewoong Pharmaceutical Co Ltd, DoNatur GmbH, Flex Pharma Inc, Grunenthal GmbH,...

2022-04-20 - Where's the Congressional Champion on Pharma Patent ...

Reformers, in turn, need to flex their muscle right back. It's past time for Democrats to unabashedly endorse pharmaceutical IP reform.

2022-04-17 - Catalent plots $350M expansion in Indiana

The added flex will allow Catalent to tackle projects up to 4,000-liters using single-use technology or 5,000 liters using existing stainless-steel...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.5M8-80%N/A
#2
$0.8M8N/AN/A
#3
$0.1M80%$22.2M
#4
$0.8M8N/AN/A
#5
$0.1M8-38%$7M